Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
about
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.Advancing Immunotherapy in Metastatic Breast Cancer.De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.Treating breast cancer with cell-based approaches: an overview.Data integration from pathology slides for quantitative imaging of multiple cell types within the tumor immune cell infiltrate.DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.Immunotherapy for Breast Cancer: What Are We Missing?Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.The Predictive and Prognostic Role of Stromal Tumor-infiltrating Lymphocytes in HER2-positive Breast Cancer with Trastuzumab-based Treatment: a Meta-analysis and Systematic Review.Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.Long-responders to anti-HER2 therapies: A case report and review of the literature.Immune gene expression and response to chemotherapy in advanced breast cancer.FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment.The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in IClinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy.Triple-negative and HER2-overexpressing breast cancer cell sialylation impacts tumor microenvironment T-lymphocyte subset recruitment: a possible mechanism of tumor escape.Immune characterization of breast cancer metastases: prognostic implications.Is there a role for immunotherapy in HER2-positive breast cancer?
P2860
Q38373249-5E60A2B7-FA88-4225-B61C-C756848A1FECQ38639746-16275559-BE29-4E5F-A1FD-93E463BCB4D4Q39324161-ED43F050-F705-44F7-AC06-26134D99BB5FQ39421814-1E00107D-F0A1-4476-B40F-B5F05C1F5DFFQ39448180-77DDA659-427A-4882-A3AD-D24C3B67450FQ41705524-064BF812-1C81-4989-A6CA-A70DA5D9F6D3Q42644167-C3F1E5B4-04E1-49D3-97C5-C1A83BBE7463Q44668850-F3307CE7-16B5-457F-B5D0-7D6BEE3F20B4Q47103332-76C8C8CA-EF38-433E-8025-BBAEFC54A6B7Q47109695-DF919F91-E49F-4629-B2BE-6CE54ED9632EQ47813921-F85033BD-8F1F-443F-AAE7-67CAA9E3BD67Q47921924-8B3C2861-5B30-4703-BE79-56A61EDCD3CAQ49311135-CED8A27F-5E47-4E83-9C27-D1B86EF3C037Q49689455-1D4B2C0A-0811-4F0F-879F-B72C9BD65043Q52599656-04335F56-1D4D-473F-84CE-675E3CBCDB2FQ53079838-2F366DDE-FD70-4702-863B-F64535B0B5AAQ53175758-3379E1E4-CE31-4699-A1C9-1FC67F787940Q54685474-59D3E73B-93B6-4E79-BF6C-BD341D8196E5Q55275119-E1AC492B-2B22-4BB7-A07C-32C8E18CF53EQ55374172-152982F7-4730-4C1D-B557-58540B9DECADQ55450758-9D4369C8-4FAE-4C69-96B3-7F7C46984D54Q57107866-94AF8D29-A032-4F25-BE29-F2EAA501F8F7
P2860
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Tumour-infiltrating lymphocyte ...... alysis of the CLEOPATRA study.
@en
type
label
Tumour-infiltrating lymphocyte ...... alysis of the CLEOPATRA study.
@en
prefLabel
Tumour-infiltrating lymphocyte ...... alysis of the CLEOPATRA study.
@en
P2093
P2860
P50
P1433
P1476
Tumour-infiltrating lymphocyte ...... alysis of the CLEOPATRA study.
@en
P2093
Astrid Kiermaier
Emma Clark
Jennifer Eng-Wong
Peter Savas
Roberto Salgado
Stephen J Luen
P2860
P356
10.1016/S1470-2045(16)30631-3
P577
2016-12-06T00:00:00Z